Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
- Conditions
- Immunotherapy Gastrict Cancer
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05699655
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
- Conditions
- Gastric CancerGastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 140
- Registration Number
- NCT05687357
- Locations
- 🇨🇳
Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳Wuhan Tongji Hospital, Wuhan, Hubei, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- Procedure: Intraperitoneal chemotherapy with paclitaxel
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2022-11-25
- Target Recruit Count
- 30
- Registration Number
- NCT05627414
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
- Conditions
- HER2-positive Gastric Cancer
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 55
- Registration Number
- NCT05586061
- Locations
- 🇨🇳
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
- Conditions
- Locally Advanced Gastric Cancer
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 203
- Registration Number
- NCT05524974
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
- Conditions
- Advanced Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05403242
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, China
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
- Conditions
- Metastatic or Recurrent Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Liangjun Zhu M.M.
- Target Recruit Count
- 38
- Registration Number
- NCT05237349
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-02-08
- Target Recruit Count
- 180
- Registration Number
- NCT05228743
- Locations
- 🇨🇳
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
- Conditions
- SintilimabGastric or Gastroesophageal Junction AdenocarcinomaLocally Advanced Solid TumorS-1HER2-positiveImmunotherapyOxaliplatin
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Aiping Zhou
- Target Recruit Count
- 44
- Registration Number
- NCT05218148
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 626
- Registration Number
- NCT05144854
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇯🇵IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.